Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DF6BU4
|
|||
| Drug Name |
YH002
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Biocytogen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | OX40L receptor (CD134) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Wnt Signaling Pathway | ||||
| Pathway Interaction Database | Downstream signaling in naï | |||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04353102) A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Biocytogen | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.